CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: GSTO2 (ImmuneEditome ID:119391)

1. Gene summary of enriched editing regions for GSTO2

check button Gene summary
Gene informationGene symbol

GSTO2

Gene ID

119391

GeneSynonymsGSTO 2-2|bA127L20.1
GeneCytomap

10q25.1

GeneTypeprotein-coding
GeneDescriptionglutathione S-transferase omega-2|GSTO-2|MMA(V) reductase|bA127L20.1 (novel glutathione-S-transferase)|glutathione S-transferase omega 2-2|glutathione-S-transferase-like protein|glutathione-dependent dehydroascorbate reductase|monomethylarsonic acid reductase
GeneModificationdate20230517
UniprotIDQ9H4Y5
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr10:104282294-104284342:+ENST00000473401.4ENSG00000065621.13GSTO2ncRNA_intronicMER63B,AluJo,AluJr,AluJbchr10:104282294-104284342:+.alignment
chr10:104282294-104284342:+ENST00000477078.2ENSG00000065621.13GSTO2ncRNA_intronicMER63B,AluJo,AluJr,AluJbchr10:104282294-104284342:+.alignment
chr10:104285500-104285778:+ENST00000473401.4ENSG00000065621.13GSTO2ncRNA_intronicAluJbchr10:104285500-104285778:+.alignment
chr10:104285500-104285778:+ENST00000477078.2ENSG00000065621.13GSTO2ncRNA_intronicAluJbchr10:104285500-104285778:+.alignment
chr10:104289129-104290495:+ENST00000467629.1ENSG00000065621.13GSTO2ncRNA_intronicAluSz,AluJb,L1MA1chr10:104289129-104290495:+.alignment
chr10:104289129-104290495:+ENST00000473401.4ENSG00000065621.13GSTO2ncRNA_intronicAluSz,AluJb,L1MA1chr10:104289129-104290495:+.alignment
chr10:104289129-104290495:+ENST00000477078.2ENSG00000065621.13GSTO2ncRNA_intronicAluSz,AluJb,L1MA1chr10:104289129-104290495:+.alignment
chr10:104293448-104293705:+ENST00000467629.1ENSG00000065621.13GSTO2ncRNA_intronicAluJbchr10:104293448-104293705:+.alignment
chr10:104293448-104293705:+ENST00000473401.4ENSG00000065621.13GSTO2ncRNA_intronicAluJbchr10:104293448-104293705:+.alignment
chr10:104296340-104297067:+ENST00000498052.1ENSG00000065621.13GSTO2ncRNA_exonicAluJb,LTR79,AluSpchr10:104296340-104297067:+.alignment
chr10:104301991-104302257:+ENST00000369707.2ENSG00000065621.13GSTO2UTR3THE1Cchr10:104301991-104302257:+.alignment


Top

2. Tumor-specific enriched editing regions for GSTO2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr10:104301991-104302257:+BRCAEER4.4720e-06image
ENSG00000065621.13,GSTO2BRCAEAG6.2789e-04image
ENSG00000065621.13,GSTO2KIRCEAG7.4630e-03image
ENSG00000065621.13,GSTO2THCAEAG2.2190e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for GSTO2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

4. Enriched editing regions and immune related splicing for GSTO2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000065621.13,GSTO2
ESCAEAGA3ENSG00000117480.11chr146410625:46410854:46411611:46411651:46411319:46411651-0.31662.7562e-029.2363e-10-0.5425imageNADAR;CNBP;CSTF2T;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FUS;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP3;LARP4B;LIN28B;MOV10;NOP56;NOP58;NUMA1;PTBP1;RBFOX2;RBM10;SAFB2;SF3B4;SLTM;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;U2AF1;U2AF2;UPF1NAT_cells_gamma_deltaGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE

More results



Top

5. Enriched editing regions and immune infiltration for GSTO2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr10:104282294-104284342:+BRCAEERT_cells_CD81.9431e-02-0.3296image
chr10:104289129-104290495:+BRCAEERMast_cells_activated1.0950e-020.2866image
chr10:104296340-104297067:+BRCAEERT_cells_CD4_memory_resting3.6952e-03-0.2054image
chr10:104301991-104302257:+BRCAEERMast_cells_activated1.2537e-020.1574image
ENSG00000065621.13,GSTO2BRCAEAGMacrophages_M03.5208e-020.1037image
ENSG00000065621.13,GSTO2CESCEAGNK_cells_activated2.5230e-030.3800image
chr10:104282294-104284342:+ESCAEERDendritic_cells_resting3.5570e-030.3165image
chr10:104296340-104297067:+ESCAEERT_cells_gamma_delta7.0791e-030.2852image
chr10:104301991-104302257:+ESCAEERMacrophages_M24.8988e-020.2379image
ENSG00000065621.13,GSTO2ESCAEAGT_cells_CD81.4469e-020.2275image
ENSG00000065621.13,GSTO2HNSCEAGB_cells_naive4.1481e-02-0.3949image
ENSG00000065621.13,GSTO2KIRCEAGNeutrophils2.4154e-020.4496image
chr10:104301991-104302257:+KIRPEERB_cells_naive7.1852e-030.5448image
ENSG00000065621.13,GSTO2KIRPEAGMacrophages_M03.7471e-020.3222image
ENSG00000065621.13,GSTO2LUADEAGMast_cells_resting2.3126e-030.4628image
chr10:104296340-104297067:+LUSCEERMacrophages_M24.7123e-020.3593image
chr10:104301991-104302257:+LUSCEERT_cells_CD88.7225e-030.3708image
ENSG00000065621.13,GSTO2LUSCEAGT_cells_CD84.0362e-020.2457image
chr10:104282294-104284342:+OVEERB_cells_memory4.9269e-02-0.2091image
chr10:104289129-104290495:+OVEERT_cells_gamma_delta2.6764e-02-0.2524image
ENSG00000065621.13,GSTO2OVEAGEosinophils3.3412e-030.2238image
ENSG00000065621.13,GSTO2PAADEAGMacrophages_M12.3965e-020.3809image
chr10:104301991-104302257:+PCPGEERT_cells_CD81.0016e-02-0.4486image
ENSG00000065621.13,GSTO2PCPGEAGT_cells_CD84.0643e-02-0.3251image
chr10:104296340-104297067:+PRADEERMonocytes1.9736e-02-0.3980image
chr10:104301991-104302257:+PRADEERDendritic_cells_activated4.4506e-04-0.3515image
ENSG00000065621.13,GSTO2PRADEAGMonocytes3.6268e-03-0.2583image
chr10:104282294-104284342:+STADEERMacrophages_M03.3128e-030.2789image
chr10:104301991-104302257:+STADEERDendritic_cells_activated1.2987e-020.2567image
ENSG00000065621.13,GSTO2STADEAGNK_cells_activated1.2142e-02-0.1736image
chr10:104301991-104302257:+THCAEERT_cells_CD4_memory_activated4.1741e-060.4591image
ENSG00000065621.13,GSTO2THCAEAGT_cells_CD4_memory_activated3.2967e-040.3173image
chr10:104301991-104302257:+UCECEERT_cells_follicular_helper1.7486e-020.5012image


Top

6. Enriched editing regions and immune gene sets for GSTO2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr10:104296340-104297067:+BLCAGSVA_HALLMARK_NOTCH_SIGNALINGEER2.0339e-030.4790image
ENSG00000065621.13,GSTO2BLCAGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.7569e-020.2693image
chr10:104282294-104284342:+BRCAGSVA_HALLMARK_DNA_REPAIREER7.1259e-03-0.3760image
chr10:104289129-104290495:+BRCAGSVA_HALLMARK_GLYCOLYSISEER2.7275e-040.4012image
chr10:104296340-104297067:+BRCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.5221e-040.2515image
ENSG00000065621.13,GSTO2BRCAGSVA_HALLMARK_P53_PATHWAYEAG1.3658e-040.1866image
chr10:104301991-104302257:+BRCAGSVA_HALLMARK_APOPTOSISEER1.0242e-030.2061image
ENSG00000065621.13,GSTO2CESCGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG4.2691e-02-0.2604image
ENSG00000065621.13,GSTO2COADGSVA_HALLMARK_APICAL_SURFACEEAG3.6547e-020.3092image
ENSG00000065621.13,GSTO2ESCAGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.7372e-030.2616image
chr10:104285500-104285778:+ESCAGSVA_HALLMARK_UV_RESPONSE_DNEER1.8304e-030.5719image
chr10:104282294-104284342:+ESCAGSVA_HALLMARK_APICAL_SURFACEEER2.1192e-020.2527image
chr10:104296340-104297067:+ESCAGSVA_HALLMARK_MITOTIC_SPINDLEEER5.7221e-03-0.2923image
chr10:104301991-104302257:+ESCAGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER7.8846e-030.3174image
chr10:104289129-104290495:+ESCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER1.4852e-020.2666image
ENSG00000065621.13,GSTO2HNSCGSVA_HALLMARK_G2M_CHECKPOINTEAG2.3371e-03-0.5609image
ENSG00000065621.13,GSTO2KIRPGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG7.7487e-030.4053image
chr10:104301991-104302257:+KIRPGSVA_HALLMARK_UV_RESPONSE_UPEER9.5828e-030.5282image
chr10:104301991-104302257:+LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.3608e-020.3503image
ENSG00000065621.13,GSTO2LUSCGSVA_HALLMARK_ADIPOGENESISEAG2.5497e-02-0.2669image
ENSG00000065621.13,GSTO2OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG1.5045e-02-0.1862image
chr10:104296340-104297067:+OVGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER4.0881e-020.2236image
chr10:104301991-104302257:+OVGSVA_HALLMARK_COMPLEMENTEER3.0954e-050.3861image
chr10:104282294-104284342:+OVGSVA_HALLMARK_KRAS_SIGNALING_DNEER3.3160e-030.3080image
ENSG00000065621.13,GSTO2PAADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG7.7753e-030.4425image
chr10:104301991-104302257:+PCPGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER2.0358e-02-0.4083image
ENSG00000065621.13,GSTO2PCPGGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.3500e-02-0.3875image
ENSG00000065621.13,GSTO2PRADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.9211e-03-0.2749image
chr10:104296340-104297067:+PRADGSVA_HALLMARK_COAGULATIONEER1.4695e-020.4149image
chr10:104301991-104302257:+PRADGSVA_HALLMARK_DNA_REPAIREER1.7465e-020.2421image
chr10:104296340-104297067:+STADGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEER3.0250e-020.1909image
chr10:104301991-104302257:+STADGSVA_HALLMARK_COAGULATIONEER4.0636e-030.2953image
chr10:104289129-104290495:+STADGSVA_HALLMARK_HYPOXIAEER3.7401e-040.3063image
chr10:104282294-104284342:+STADGSVA_HALLMARK_HEME_METABOLISMEER2.3031e-030.2890image
ENSG00000065621.13,GSTO2THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG5.2704e-030.2491image
chr10:104296340-104297067:+THCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER3.7931e-02-0.2807image
chr10:104301991-104302257:+THCAGSVA_HALLMARK_APOPTOSISEER3.5996e-060.4618image
ENSG00000065621.13,GSTO2UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG9.2538e-030.3880image
chr10:104301991-104302257:+UCECGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER4.1398e-030.5862image


Top

7. Enriched editing regions and drugs for GSTO2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr10:104296340-104297067:+BLCAFH535EER2.9338e-03-0.4639image
ENSG00000065621.13,GSTO2BLCAAMG.706EAG1.4756e-030.3808image
chr10:104282294-104284342:+BRCABMS.708163EER1.3837e-05-0.5728image
chr10:104289129-104290495:+BRCALenalidomideEER2.2148e-030.3415image
ENSG00000065621.13,GSTO2BRCABicalutamideEAG1.1516e-03-0.1596image
chr10:104296340-104297067:+BRCAAZD6244EER1.3000e-02-0.1763image
chr10:104301991-104302257:+BRCAABT.263EER2.2833e-020.1439image
ENSG00000065621.13,GSTO2CESCBIRB.0796EAG7.3481e-03-0.3400image
chr10:104301991-104302257:+ESCABMS.509744EER9.8902e-03-0.3086image
chr10:104282294-104284342:+ESCAAZD6482EER5.0867e-03-0.3048image
ENSG00000065621.13,GSTO2ESCAGNF.2EAG1.6387e-03-0.2904image
chr10:104296340-104297067:+ESCAAMG.706EER4.7634e-05-0.4194image
chr10:104285500-104285778:+ESCAAZD8055EER5.1431e-03-0.5228image
chr10:104301991-104302257:+HNSCAKT.inhibitor.VIIIEER2.2840e-020.4940image
ENSG00000065621.13,GSTO2HNSCDoxorubicinEAG4.2343e-030.5326image
ENSG00000065621.13,GSTO2KIRCBIBW2992EAG9.0700e-03-0.5108image
chr10:104301991-104302257:+KIRPBAY.61.3606EER6.7851e-040.6559image
ENSG00000065621.13,GSTO2LUADAZ628EAG1.7440e-020.3787image
ENSG00000065621.13,GSTO2LUSCATRAEAG2.1794e-04-0.4281image
chr10:104296340-104297067:+LUSCA.443654EER6.4397e-030.4787image
chr10:104301991-104302257:+LUSCMG.132EER3.4212e-020.3032image
ENSG00000065621.13,GSTO2OVATRAEAG1.5367e-020.1856image
chr10:104296340-104297067:+OVBIBW2992EER2.2625e-030.3288image
chr10:104301991-104302257:+OVBMS.536924EER3.3284e-03-0.2775image
chr10:104296340-104297067:+PAADBMS.754807EER6.2025e-030.5530image
ENSG00000065621.13,GSTO2PAADJNK.Inhibitor.VIIIEAG1.6941e-02-0.4011image
chr10:104301991-104302257:+PCPGCGP.60474EER2.9333e-020.3855image
ENSG00000065621.13,GSTO2PRADGW843682XEAG2.6701e-04-0.3206image
chr10:104301991-104302257:+PRADDMOGEER6.8285e-040.3407image
chr10:104296340-104297067:+PRADCyclopamineEER1.1541e-02-0.4409image
chr10:104282294-104284342:+STADGSK.650394EER1.2448e-02-0.2387image
chr10:104285500-104285778:+STADBortezomibEER4.5270e-02-0.4039image
chr10:104301991-104302257:+STADBMS.536924EER1.4995e-04-0.3832image
chr10:104289129-104290495:+STADBexaroteneEER1.3086e-02-0.2163image
ENSG00000065621.13,GSTO2THCAAICAREAG6.1820e-05-0.3517image
chr10:104296340-104297067:+THCAGW843682XEER2.1200e-020.3101image
chr10:104301991-104302257:+THCAAICAREER3.3064e-06-0.4633image
chr10:104301991-104302257:+UCECEmbelinEER8.5641e-030.5460image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr10:104301991-104302257:+ENST00000369707.2Q9H4Y5DB00143GlutathioneSmallMoleculeDrug